Anh Tu Nguyen - 24 Feb 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Medical Officer
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
24 Feb 2026
Net transactions value
-$201,584
Form type
4
Filing time
25 Feb 2026, 18:03:14 UTC
Previous filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nguyen Anh Tu Chief Medical Officer C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht, Attorney-in-Fact 25 Feb 2026 0002058704

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $201,584 -29,300 -6.9% $6.88 395,023 24 Feb 2026 Direct F1
holding XERS Common Stock 3,710 24 Feb 2026 By IRA F2
holding XERS Common Stock 3,501 24 Feb 2026 By children's IRA F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of February 24, 2026.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Chief Medical Officer